The Cancer Epidemiology Program (CEP) brings together 25 investigators from 11 Departments at Stanford and the Northern California Cancer Center (NCCC) in a collaborative approach to reducing the burden, incidence, mortality and morbidity of cancer through innovative and interdisciplinary epidemiologic research. This goal is accomplished through observational research in four areas: cancer surveillance;cancer etiology and risk assessment;early cancer detection;and cancer treatment, prognosis and quality of life. The study of disparities among racial/ethnic/cultural groups forms a theme cross cutting all of these areas.
The specific aims of the four targeted research areas are: ? Cancer surveillance: Describe cancer risk factors and spatial and temporal trends in cancer incidence and mortality;identify scientific hypotheses for further study;conduct methodologic studies to improve data quality;and gather data as new technologies and treatments are introduced into medical practice. ? Cancer etiology and risk assessment: Convene multidisciplinary expertise to study the complex interactions of molecular, genetic, behavioral and environment factors that affect cancer occurrence. ? Early detection of cancer: Evaluate the use of new technologies to detect cancers before they have spread and increase understanding of the risks and benefits of screening. ? Cancer care, prognosis and quality of life: Conduct observational studies of cancer treatments and other cancer care to determine their diffusion, utilization and effect on patient outcomes by characteristics of patients, providers and delivery systems. Identify genetic, molecular and other determinants of recurrence and survival in cancer patients, and factors related to quality of life for cancer patients and families.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Lee, Bee L; Fan, Shenghua K; Lu, Ying (2017) A curve-free Bayesian decision-theoretic design for two-agent Phase I trials. J Biopharm Stat 27:34-43
Mohanty, Suchismita; Chen, Zixin; Li, Kai et al. (2017) A Novel Theranostic Strategy for MMP-14-Expressing Glioblastomas Impacts Survival. Mol Cancer Ther 16:1909-1921
Alcántara-Hernández, Marcela; Leylek, Rebecca; Wagar, Lisa E et al. (2017) High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization. Immunity 47:1037-1050.e6
Chao, Mark P; Gentles, Andrew J; Chatterjee, Susmita et al. (2017) Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell 20:329-344.e7
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2017) A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods 14:737-742
Sun, Ruping; Hu, Zheng; Sottoriva, Andrea et al. (2017) Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nat Genet 49:1015-1024
Jin, Yuxue; Lai, Tze Leung (2017) A new approach to regression analysis of censored competing-risks data. Lifetime Data Anal 23:605-625
Clarke, Christina A; Glaser, Sally L; Leung, Rita et al. (2017) Prevalence and characteristics of cancer patients receiving care from single vs. multiple institutions. Cancer Epidemiol 46:27-33
Han, Summer S; Ten Haaf, Kevin; Hazelton, William D et al. (2017) The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer 140:2436-2443
Wender, Paul A; Hardman, Clayton T; Ho, Stephen et al. (2017) Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 358:218-223

Showing the most recent 10 out of 227 publications